China Morquio Syndrome (MPS-IV) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Morquio Syndrome (MPS-IV) is a rare metabolic condition in which the body is unable to break down long chains of sugar molecules called glycosaminoglycans. As a result, toxic levels of these sugars accumulate in cell structures called lysosomes, leading to the various signs and symptoms associated with the condition. The global prevalence of MPS IV is estimated to occur in 1 in 200,000 to 300,000 individuals.
China is a growing market for Morquio syndrome (MPS-IV) due to factors such as increase in global prevalence rate (1 in 200,000 to 300,000 individuals). Other factors that are contributes to the growth of market are awareness campaign by various organizations, affordable reimbursement scenario for treatment, the growing necessity for advanced therapeutics and improved R&D activities.
However, there are some restraining factors for growth of Morquio syndrome (MPS-IV) therapeutics market in China such as high cost of medicines, misdiagnosis of the disease and lack of innovative therapies.